Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, is currently under FDA review.

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, is currently under FDA review.

The US Food and Drug Administration has placed its most serious warning — a so-called black-box warning — on a drug used to relieve menopausal hot flashes.

People in the Veozah group had fewer sleep issues vs. those on a placebo at weeks 4 and 12. Improvements in sleep were sustained throughout the study. Improvement in quality of life .

About VEOZAH (fezolinetant)VEOZAH (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist approved in the U.S. for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

An experimental once-a-day pill that works without hormones significantly reduced the number of hot flashes experienced by women going through menopause and improved their sleep compared to a ...

Today, Astellas Pharma Canada, Inc. is proud to announce the Health Canada approval of VEOZAH® (fezolinetant film-coated tablets), the first and only non-hormonal treatment indicated for the ...

The Food and Drug Administration (FDA) has updated the prescribing information for Veozah (fezolinetant) to include a warning regarding the risk of serious liver injury.. Approved in May 2023 ...

The US Food and Drug Administration has placed its most serious warning — a so-called black-box warning — on a drug used to relieve menopausal hot flashes.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZAH™ (fezolinetant), its first-in-class treatment for moderate to severe vasomotor symptoms (VMS ...